Source comparison
MK-677 Oral Ghrelin Receptor Agonism: Research Applications Comparison
MK-677's unique profile. Oral bioavailability, extended half-life, selective ghrelin receptor agonism. Makes it suited to specific experimental contexts. The table below compares MK-677 to alternative approaches for modulating the GH/IGF-1 axis. MK-677 Oral Gh
This comparison does not assign a generated winner or score.
- MK-677's unique profile. Oral bioavailability, extended half-life, selective ghrelin receptor agonism. Makes it suited to specific experimental contexts. The table below compares MK-677 to alternative approaches for modulating the GH/IGF-1 axis.
- MK-677 Oral Ghrelin Receptor Agonism
- Oral, once daily
- 24 hours
- GHS-R1a agonism → pulsatile GH secretion
- No injections; preserves physiological feedback
- Best for long-term studies requiring consistent GH elevation without injection variables or compliance issues
- Injectable GHRP-6 or Ipamorelin
- Subcutaneous, 1–3× daily
- 30–90 minutes
- GHS-R1a agonism → acute GH pulse
- Synergizes with GHRH for supra-physiological peaks
- Best for acute GH response studies or protocols combining ghrelin + GHRH pathways
- Exogenous Recombinant GH
- Subcutaneous, daily
- 2–4 hours
- Direct GH receptor activation
- Bypasses endogenous secretion entirely
- Best when precise GH dosing or receptor-level investigation is required; suppresses endogenous production
- CJC-1295 (GHRH analog)
- Subcutaneous, 1–2× weekly
- 6–8 days
- GHRH receptor agonism → prolonged GH release
- Extended duration; amplifies endogenous GH without ghrelin pathway
- Best for models where GHRH pathway is the focus or where weekly dosing simplifies protocol
- Nutrient Timing (Fasting/Exercise)
- Behavioral intervention
- N/A
- Endogenous ghrelin + GH secretion
- No pharmacological intervention; models natural physiological state
- Best for baseline physiology studies; limited control over GH magnitude
- MK-677 oral ghrelin receptor agonism fits models where injectable protocols introduce confounding variables. Handling stress in rodents, compliance variability in long-duration primate studies, or reconstitution errors in multi-site trials. It also models the ghrelin pathway specifically, which matters in cachexia, anorexia, or aging research where appetite and GH are both endpoints of interest.